In a breakthrough for Alzheimer’s treatment in India, pharmaceutical giant Eli Lilly has launched donanemab in the Indian market under the brand name Lormalzi. The once-a-month 350 mg infusion has been shown to slow the progression of the disease by dissolving the amyloid beta protein plaques in the brain — proven to be a classical sign of the neuro-degenerative disease. The innovative drug — third to be approved for the disease by the US Food and Drug Administration (USFDA) and the first one to be launched in India — will be prohibitively expensive. A single dose of the drug might cost Rs 91,688.…